1 | Risankizumab | [1] Risankizumab Risankizumab | [1] Risankizumab
Risankizumab
💬
| [1] IL23A IL23A 💬
| [9] C-type lectin receptor signaling pathway C-type lectin receptor signaling pathway, Cytokine-cytokine receptor interaction, Inflammatory bowel disease, JAK-STAT signaling pathway, Pathways in cancer, Pertussis, Rheumatoid arthritis, Th17 cell differentiation, Tuberculosis 💬 | [4] 37 37, 96, 97, 271 💬
|
2 | Risankizumab (Genetical Recombination) | [1] Risankizumab Risankizumab | [1] Risankizumab
Risankizumab
💬
| [1] IL23A IL23A 💬
| [9] C-type lectin receptor signaling pathway C-type lectin receptor signaling pathway, Cytokine-cytokine receptor interaction, Inflammatory bowel disease, JAK-STAT signaling pathway, Pathways in cancer, Pertussis, Rheumatoid arthritis, Th17 cell differentiation, Tuberculosis 💬 | [1] 97 97 💬
|
3 | Risankizumab 10 mg/ml | [1] Risankizumab Risankizumab | [1] Risankizumab
Risankizumab
💬
| [1] IL23A IL23A 💬
| [9] C-type lectin receptor signaling pathway C-type lectin receptor signaling pathway, Cytokine-cytokine receptor interaction, Inflammatory bowel disease, JAK-STAT signaling pathway, Pathways in cancer, Pertussis, Rheumatoid arthritis, Th17 cell differentiation, Tuberculosis 💬 | [1] 96 96 💬
|
4 | Risankizumab 180 mg SC | [1] Risankizumab Risankizumab | [1] Risankizumab
Risankizumab
💬
| [1] IL23A IL23A 💬
| [9] C-type lectin receptor signaling pathway C-type lectin receptor signaling pathway, Cytokine-cytokine receptor interaction, Inflammatory bowel disease, JAK-STAT signaling pathway, Pathways in cancer, Pertussis, Rheumatoid arthritis, Th17 cell differentiation, Tuberculosis 💬 | [1] 96 96 💬
|
5 | Risankizumab 600 mg IV | [1] Risankizumab Risankizumab | [1] Risankizumab
Risankizumab
💬
| [1] IL23A IL23A 💬
| [9] C-type lectin receptor signaling pathway C-type lectin receptor signaling pathway, Cytokine-cytokine receptor interaction, Inflammatory bowel disease, JAK-STAT signaling pathway, Pathways in cancer, Pertussis, Rheumatoid arthritis, Th17 cell differentiation, Tuberculosis 💬 | [1] 96 96 💬
|
6 | Risankizumab 90 mg/ml | [1] Risankizumab Risankizumab | [1] Risankizumab
Risankizumab
💬
| [1] IL23A IL23A 💬
| [9] C-type lectin receptor signaling pathway C-type lectin receptor signaling pathway, Cytokine-cytokine receptor interaction, Inflammatory bowel disease, JAK-STAT signaling pathway, Pathways in cancer, Pertussis, Rheumatoid arthritis, Th17 cell differentiation, Tuberculosis 💬 | [1] 96 96 💬
|
7 | Risankizumab IV | [1] Risankizumab Risankizumab | [1] Risankizumab
Risankizumab
💬
| [1] IL23A IL23A 💬
| [9] C-type lectin receptor signaling pathway C-type lectin receptor signaling pathway, Cytokine-cytokine receptor interaction, Inflammatory bowel disease, JAK-STAT signaling pathway, Pathways in cancer, Pertussis, Rheumatoid arthritis, Th17 cell differentiation, Tuberculosis 💬 | [2] 96 96, 97 💬
|
8 | Risankizumab On-Body Injector (OBI) | [1] Risankizumab Risankizumab | [1] Risankizumab
Risankizumab
💬
| [1] IL23A IL23A 💬
| [9] C-type lectin receptor signaling pathway C-type lectin receptor signaling pathway, Cytokine-cytokine receptor interaction, Inflammatory bowel disease, JAK-STAT signaling pathway, Pathways in cancer, Pertussis, Rheumatoid arthritis, Th17 cell differentiation, Tuberculosis 💬 | [1] 96 96 💬
|
9 | Risankizumab SC | [1] Risankizumab Risankizumab | [1] Risankizumab
Risankizumab
💬
| [1] IL23A IL23A 💬
| [9] C-type lectin receptor signaling pathway C-type lectin receptor signaling pathway, Cytokine-cytokine receptor interaction, Inflammatory bowel disease, JAK-STAT signaling pathway, Pathways in cancer, Pertussis, Rheumatoid arthritis, Th17 cell differentiation, Tuberculosis 💬 | [2] 96 96, 97 💬
|